Premium
Biosimilars: ensuring safety in the search for savings
Author(s) -
Greener Mark
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1560
Subject(s) - biosimilar , pharmacovigilance , medicine , risk analysis (engineering) , brand names , pharmacology , marketing , adverse effect , business
Biosimilars – cheaper versions of biopharmaceuticals produced by competing companies – have the potential to reduce the NHS drugs bill substantially. However, unlike generic drugs, biosimilars are not interchangeable with the original brand, raising safety concerns. Hence pharmacovigilance and prescribing by brand is essential.